
Application of n-of-1 clinical trials in personalized nutrition research: a trial protocol for Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR)

Yunyi Tian, MSc¹; Yue Ma, PhD^{1,2}; Yuanqing Fu, PhD^{1,2}, Ju-Sheng Zheng, PhD^{1,2*}

¹Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Key Laboratory of Growth Regulation and Translation Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China

² Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, China

*Corresponding author:

Ju-Sheng Zheng, PhD

Zhejiang Provincial Laboratory of Life Sciences and Biomedicine, Key Laboratory of Growth Regulation and Translation Research of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Rd, Cloud Town, Hangzhou, China.

Tel: +86 (0)57186915303

Email: zhengjusheng@westlake.edu.cn

Yunyi Tian, Yue Ma, Yuanqing Fu and Ju-Sheng Zheng report no conflicts of interest.

This study was funded by National Natural Science Foundation of China (81903316), Zhejiang Ten-thousand Talents Program (2019R52039) and Westlake University (101396021801).

Trial registration: [Clinicaltrials.gov](https://clinicaltrials.gov) (NCT04125602)

Abbreviations used: AUC24, area under the curve; CGM, continuous glucose monitoring; HF-LC, high-fat, low-carbohydrate; LF-HC, low-fat, high-carbohydrate; MAGE, mean amplitude of glycemic excursions; PMG, postprandial maximum glucose; WE-MACNUTR, Westlake N-of-1 Trials for Macronutrient Intake.

1 **Abstract**

2 Personalized dietary recommendations can help with more effective disease
3 prevention. This study aims to investigate the individual postprandial glucose
4 response to diets with diverse macronutrient proportions at both individual level and
5 population level and explore the potential of the novel single-patient (n-of-1) trial for
6 the personalization of diet. Secondary outcomes include individual phenotypic
7 response and the effects of dietary ingredients on the composition and structure of gut
8 microbiota. Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) is a
9 multiple crossover feeding trial consisting of three successive 12-day dietary
10 intervention pairs including a 6-day wash-out period before each 6-day isocaloric
11 dietary intervention (a 6-day high-fat, low-carbohydrate (HF-LC) diet and a 6-day
12 low-fat, high-carbohydrate (LF-HC) diet). The results will help provide personalized
13 dietary recommendation on macronutrients in terms of postprandial blood glucose
14 response. Well-designed n-of-1 trial is likely to become an effective method of
15 optimizing individual health and advancing health care. This trial is registered at
16 clinicaltrials.gov (NCT04125602).

17 **Keywords:** personalized nutrition, dietary intervention, n-of-1, single patient trial,
18 high-fat diet, low carbohydrate diet, postprandial blood glucose, gut microbiome

19

20 **Introduction**

21 Diet and nutrition are key to maintain human health. Previous studies have showed
22 much interest in the metabolic effects of different ratios of dietary fat to carbohydrate
23 intake(1-5). Some evidence suggests that a high-fat, low-carbohydrate (HF-LC) diet
24 can improve glycemic control by reducing glycated hemoglobin and fasting glucose,
25 while others support the beneficial effect of a low-fat, high-carbohydrate (LF-HC)
26 diet with particular focus on the quality of carbohydrate(1, 6-10). One important
27 interpretation for the inconsistent results is the individualized or personalized
28 response to the dietary macronutrient intake, which is also called “personalized
29 nutrition”(11).

30

31 Personalized nutrition focuses on an individual's potentially unique dietary needs
32 instead of assuming a “one-size-fits-all” approach where everyone is thought to
33 benefit from the same diet (12). The general aim of personalized nutrition is to
34 improve health using nutritional, genetic, phenotypic and other information of the
35 individuals to develop targeted nutritional advice, services or other products(13-15).
36 Although specific dietary recommendation has been made for pregnant women,
37 infants, children, adults or elderly, they are still subgroup recommendation, which is
38 far from the stage of “personalization” or “precision”.

39

40 Application of ‘n-of-1’ clinical trial or ‘single patient’ study represents a new
41 direction in personalized nutrition research (**Figure 1**). It can capture intra-individual
42 variability in health behaviors over time, aiming to identify individual response to a
43 given intervention in a controlled trial, which provides great opportunity to answer the
44 personalization potential of different diets, nutrients or nutrition supplements(16-18).
45 The idea of n-of-1 has been applied in special education, psychotherapy, psychology
46 and pharmaceutical studies for decades to test the individual response to specific
47 drugs or treatments(19-23). Stunnenberg et al. reported the efficacy of mexiletine on
48 reducing muscle stiffness in patients with nondystrophic myotonia (NDM) using a
49 series of n-of-1 trials(24). However, there is no published ‘n-of-1’ study in nutrition
50 field so far. Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) is a
51 novel series of clinical trials that use the macronutrient intake as an exemplar for the
52 new progress in the field.

53

54 We will describe the trial protocol of the WE-MACNUTR: a series of n-of-1 feeding
55 clinical trials among healthy adults. The feeding trial is composed of two dietary
56 interventions, a HF-LC diet and a LF-HC diet. The primary objective is to investigate
57 the response of postprandial blood glucose to the dietary interventions and the
58 primary outcomes include postprandial maximum glucose (PMG), the area under the
59 curve (AUC₂₄) of postprandial glucose from 0.00 to 24.00 and the mean amplitude of
60 glycemic excursions (MAGE) obtained by measuring the arithmetic mean of the

61 differences between consecutive peaks and nadirs. Secondary objectives of this study
62 include evaluating different phenotypic responses, such as circulating lipid profile
63 changes to a specific diet among individuals and evaluating the impact of different
64 dietary components on the composition and structure of gut microbiota.

65

66 **Methods**

67 **Study Design**

68 The present n-of-1 trial is a multiple crossover feeding trial conducted in a single
69 participant, comparing her/his response to different interventions and assessing the
70 variability in these responses(25). In the WE-MACNUTR study, a series of n-of-1
71 trials are employed simultaneously and a common regimen of interventions is applied
72 to all participants (**Figure 2**). Participants experience three successive 12-day
73 intervention pairs including a 6-day wash-out period between each intervention. The
74 diets are isocaloric and all provided by the researchers, and the primary distinguishing
75 feature is their fat and carbohydrate contents, including a HF-LC diet and a LF-HC
76 diet. Prior studies have shown that dietary pattern may have a rapid influence on
77 glycemic control. Parr and colleagues performed an intervention study and
78 successfully observed a significant effect of high-carbohydrate diet (compared with a
79 high-fat diet) on various blood glucose measurements after a 5-day intervention(26).
80 In addition, gut microbial community was also reported to change substantially in
81 response to the dietary change within four days(27). Therefore, we set a wash-out

82 period of six days between each intervention arm (HF-LC and LF-HC), after
83 balancing the outcomes of the study (postprandial glycemic response, gut microbiota
84 change), and feasibility of the present feeding trials. Each 12-day intervention pair
85 comprises 6 days of HF-LC (three meals daily) and 6 days of LF-HC (three meals
86 daily) diets in a random order. The order of the diets in each pair is determined using
87 a block randomization. Major investigators and laboratory personnel responsible for
88 the measurements are masked to group allocation. Meal providers are aware of group
89 and diet allocation, but they are not involved in the rest of the trial.

90

91 Participants are required to complete a basic questionnaire on a daily basis after
92 dinner to summarize their eating behaviors and multiple lifestyle factors including
93 physical activity, mood and sleep patterns throughout the day. Biological samples
94 including blood, saliva, urine and fecal samples will be collected every 6 days for
95 metabolomics profiling using untargeted platforms. Saliva will also be collected for
96 oral microbiota investigation (**Figure 3**). The fasting venous blood samples will be
97 collected every 6 days only during the first set of the study as to reduce the burden
98 and increase the compliance of the participants. The participants will be asked to wear
99 a continuous glucose monitoring (CGM, Freestyle Libre Pro System), which measures
100 interstitial glucose every 15 minutes. The same CGM system was used by a recent
101 personalized nutrition study (PREDICT 1) to monitor individual postprandial
102 glycemic responses(28). As most individuals do not resemble “the average” in the

103 context of precision nutrition, using data sets generated from digital wearable devices,
104 such as CGM, will potentially help inform individualized food choices(29). In the
105 present study, participants will be asked to wear the sensor two days before the start
106 of each intervention period, and remove it by the end of each 6-day intervention
107 period. CGM will not be used during the washout periods. In addition, participants are
108 asked to continue their regular daily activities and exercise throughout the study
109 period, and wear a wrist-based triaxial accelerometer (AX3, Axivity) on the
110 non-dominant wrist to monitor the physical activity and exercise intensity during the
111 intervention period.

112

113 The study was approved by the Westlake University Internal Ethical Review Board in
114 Hangzhou, China, and registered with ClinicalTrials.gov (identifier: NCT04125602).

115 Written informed consent are obtained from all study participants.

116

117 **Dietary Intervention**

118 A dietitian designs the diet for the intervention and the washout period based on the
119 Chinese Dietary Guidelines (2016) and Chinese Dietary Reference Intakes (2013) as
120 well as the participants' demographic information, eating habits and physical activity
121 levels(30, 31). Besides, factors such as local food availability, the cooking methods of
122 the Westlake University canteen kitchen, and the current recipes are important factors

123 in the meal planning. Participants are instructed to consume only the provided foods
124 or beverages.

125

126 *Wash-out Diet (WD)*

127 Prior to each dietary intervention, all participants are provided with the same
128 standardized diets for 6 days as the ‘wash-out diet’ to reduce potential sources of bias
129 and eliminate any carry-over effect of previous intervention. The wash-out diet
130 consists of 30% of total energy (%E) from fat, 15%E from protein and 55%E from
131 carbohydrate based on the acceptable macronutrient distribution range (AMDR)(32).

132

133 *HF-LC Diet Intervention*

134 Throughout the 6-day HF-LC intervention, participants are provided with a HF-LC
135 diet, including a three-day diet consisting of 60%E from fat, 15%E from protein and
136 25%E from carbohydrate while the other three-day diet consisting of 70%E from fat,
137 15%E from protein and 15%E from carbohydrate.

138

139 *LF-HC Diet Intervention*

140 Throughout the 6-day LF-HC intervention, participants are provided with a LF-HC
141 diet, including a 3-day diet consisting of 20%E from fat, 15%E from protein and
142 65%E from carbohydrate while the other 3-day diet consisting of 10%E from fat,
143 15%E from protein and 75%E from carbohydrate.

144

145 **Participants**

146 Participants are recruited among students and staffs from Westlake University,
147 Hangzhou, China. Inclusion criteria are: adults aged between 18 and 65 years;
148 participants are able to provide written informed consent, and have access to smart
149 phones or computers. Exclusion criteria include: long-term gastrointestinal diseases;
150 neurological conditions and cognitive impairment; other clinically diagnosed medical
151 conditions including type 2 diabetes, hypertension, cardiovascular diseases, liver,
152 kidney diseases and/or other systemic diseases; taking antibiotics within the last two
153 weeks; hospitalization or surgery planned within the next three months; pregnant or
154 lactating women; tobacco, alcohol, or illicit drug abuse; vegan or food allergies; with
155 no access to a smart phone or computer with an internet connection; enrolled in
156 concurrent intervention study; and non-Chinese speaking participants. This study
157 emphasizes more on assessing individual responses to the intervention of interest
158 rather than drawing a general conclusion at population level, and therefore, study
159 participants cover a broad age range and will not be balanced by sex.

160

161 **Measures**

162 The primary outcomes are (1) postprandial maximum glucose (PMG). PMG is the
163 peak value of CGM within 3 hours after the first bite of a meal or the maximum value
164 of CGM between two meals when the interval is less than 3 hours. (2) area under the

165 curve (AUC24). AUC24 refers to total area under the CGM curve from 0.00 to 24.00.
166 (3) mean amplitude of glycemic excursions (MAGE). MAGE is obtained by
167 measuring the arithmetic mean of the differences between consecutive peaks and
168 nadirs, provided that the differences are greater than 1 SD around the mean glucose
169 values. Secondary outcomes include different phenotypic responses, such as
170 circulating lipid profile and gut microbiome profile, to a specific diet among
171 individuals (**Table 1**).

172

173 **Sample Size Calculation**

174 In the present study, a total of 30 participants will be enrolled. Bayesian hierarchical
175 model meta-analysis will be applied to combine the results from each n-of-1 trial to
176 generate pooled effect estimate at population level. However, no formula-based
177 methodology exists for sample size calculation for such design at population level(33).
178 Referring to the method reported by Stunnenberg et al., we performed a
179 simulation-based statistical power calculation at population level with
180 modifications(24). In brief, a prior distribution for the mean intervention effect
181 (HF-LC vs. LF-HC) on the PMG was prespecified based on results of a previous RCT
182 reported by Parr et al(26). In their study, 1.6 mmol/L (6.2 mmol/L vs. 7.8 mmol/L)
183 difference in the PMG was established between participants receiving high-fat versus
184 high-carbohydrate meals. We drew a random realization and simulated an
185 individual-specific virtual mean intervention effect for each participant. At the next

186 level of simulation, longitudinal measurements for each participant (3 sets, 2
187 intervention periods per set and 18 observations per intervention period) were
188 simulated assuming a normal distribution of the measurements centered around the
189 individual-specific virtual mean effect size, with a common within-participant
190 residual variance. Thereafter, all the simulated data from these n-of-1 trials were used
191 to perform a multilevel Bayesian meta-analysis specifying a linear mixed model with
192 flat non-informative priors at population level.

193

194 A previous study found that the difference in PMG between healthy participants aged
195 25-45 years and those older than 45 years was 3mg/dL (0.167mmol/L)(34, 35).
196 Therefore, we considered this magnitude of difference to be clinically meaningful and
197 determined the posterior probability on both intervention effect of at least 0.167
198 mmol/L from the simulation-based Bayesian meta-analysis based on the simulation
199 data. In order to keep a balance between the power of detecting meaningful
200 differences and false positive rate, a relatively strict 90% posterior probability on an
201 intervention effect of 0.167 was treated as a clinically positive result at population
202 level, while a stricter 99% posterior probability on an intervention effect of not being
203 equal to zero was treated as a statistically positive result. We repeated the above
204 procedures for 1000 times (corresponding with data from 1000 aggregated N-of-1
205 trials) and the fraction of meta-analyses that returned a positive conclusion was

206 treated as measure for the power. Consequently, the power was estimated to be 100%
207 for detecting the intervention effect of at 0.167 mmol/L difference in PMG.

208

209 On the other hand, in order to determine the false positive rate, we performed another
210 set of simulation under the assumption of no intervention effect. For each virtual

211 participant, we simulated data that allowed the participant to have an

212 individual-specific virtual mean intervention effect which centered around the true

213 population-level mean effect size (zero) with a normal distribution. At the next level

214 of simulation, longitudinal measurements for each participant (3 sets, 2 intervention

215 periods per set and 18 observations per intervention period) were simulated assuming

216 a normal distribution of the measurements centered around the individual-specific

217 virtual mean effect size, with a common within-participant residual variance. All data

218 from these 30 virtual individual N-of-1 trials were used to perform the multilevel

219 Bayesian meta-analysis at population level. A posterior probability of more than 90%

220 on an intervention effect of 0.167 mmol/L and more than 99% on an intervention

221 effect of not being equal to zero were treated as clinically and statistically false

222 positive results, respectively. After repeating the procedures for 1000 times, the

223 fraction of meta-analyses that returned a clinically or statistically false positive

224 conclusion was determined as measure for the type I error rate at population level,

225 which was found to be 0.023 and 0.048, respectively. Thus, this simulation-based

226 sample calculation indicates that with 30 participants completing the trial (3 sets, 2

227 intervention periods per set and 18 observations per intervention period), we will have
228 satisfactory type I error rate and enough power to detect the prespecified intervention
229 effect.

230

231 **Statistical Analysis Plan**

232 **Data Management**

233 Even though all participants are students/staffs who routinely have meals in campus,
234 we anticipate that some participants will skip some meals that we provide at dining
235 room and eat other foods instead, which adds uncertainty to the effects on
236 postprandial blood glucose. On this occasion, we will ask the volunteers to record all
237 the other foods they have eaten not provided by the researchers. Other major
238 violations, such as failure to complete at least one set of intervention, will prevent
239 statistical analysis at individual level and lead to exclusion of the participants from
240 meta-analysis at population level.

241

242 **Primary Analysis**

243 The primary analysis of intervention effect is the comparison of the effect of HF-LC
244 diet with that of LF-HC diet on postprandial blood glucose level. At individual level,
245 we use individual intervention effects to guide dietary decisions for each participant.
246 On the other hand, we generate estimates of intervention effect at population level by
247 combing the n-of-1 results with meta-analysis.

248

249 **Analysis of Baseline Data**

250 Descriptive statistics with demographics and baseline characteristics will be presented

251 for each participant.

252

253 **Analysis of Individual N-of-1 Trials**

254 Statistical analysis will be performed separately for each n-of-1 trial to estimate the

255 intervention effect at individual level. Bayesian models will be applied to estimate the

256 intervention effects (**Figure 4**). Posterior probabilities of outcomes will be calculated

257 using an interface that incorporates open-source R software (3.6.1) and open-source

258 OpenBUGS (version 3.2.3). The results will be reported for primary variables (e.g.,

259 peak concentration of postprandial blood glucose and AUC of postprandial glucose

260 concentration over 24 hours), and participants will be provided with an estimate of

261 differences in the variables and the probabilities that the differences are induced by

262 the different interventions (HF-LC vs. LF-HC).

263

264 **Meta-analysis of N-of-1 Trials**

265 A Bayesian multi-level model will be used to combine results of the multiple n-of-1

266 trials(24, 36, 37). Participant will be treated as a random effect and a common

267 within-participant residual variance will be assumed. Non-informative priors will be

268 applied for all model parameters, with mean parameters using normal prior

269 distributions with very large standard deviations and variation parameters using
270 inverse gamma distributions with both shape and scale parameters equal to 0.01.
271 Using the interface that incorporates R software (3.6.1) and OpenBUGS (version
272 3.2.3), combining the data from the individual n-of-1 trials will obtain posterior
273 distributions for the mean intervention effect at the population level. Secondary and
274 exploratory outcomes will be analyzed similarly.

275

276 **Discussion**

277 To advance the field of personalized nutrition, n-of-1 clinical trial appears to be a
278 promising study design to advocate, although the real-world example is rare. We will
279 use the WE-MACNUTR trial as an exemplar to showcase the study design of n-of-1
280 trial as to test the individualized response to macronutrient intake among healthy
281 adults. The study, if successful, will provide insight into the feasibility of n-of-1
282 approach to personalize or tailor dietary intervention to individuals.

283

284 Previous study suggested that the magnitude of postprandial responses to mixed meals
285 depended largely on the total amount of fat and carbohydrates intakes(1, 5, 6). The
286 American Diabetes Association (ADA) recommends monitoring carbohydrate intake
287 to achieve better glycemic control in patients with type 2 diabetes, which is based on
288 studies showing reduced postprandial glucose and triglyceride responses in
289 individuals consuming HF-LC diets(38-40). However, previous systematic reviews

290 discussed the effects of HF-LC and LF-HC diets on metabolic risk factors and showed
291 inconsistent results(5, 7, 41). Hsu et al suggested LF-HC diet consisting of high fiber
292 contents showed beneficial effects on glucose and insulin sensitivity among both
293 Asian Americans and Caucasian Americans(42). Several studies have reported that
294 both HF-LC and LF-HC diets reduced HbA1c and fasting glucose in obese adults
295 with T2D, while HF-LC diet achieved better improvements in glycemic control(1, 2).
296 Kamada et al suggested that changes in HbA1c and fasting plasma glucose did not
297 differ significantly between HF-LC and LF-HC diets among Japanese diabetic
298 patients(43). The benefits and drawbacks of different dietary patterns on health are
299 under intensive study these days despite the lack of a standardized definition
300 regarding the macronutrient contents(44-46). Therefore, n-of-1 trial has a huge
301 potential to help explore the main effects of a specific dietary intervention, and
302 identify the factors that influence individual response to nutritional factors. In the
303 present study, it is expected that the trial will provide information on the response of
304 postprandial blood glucose level among individuals to different dietary interventions,
305 namely HF-LC and LF-HC diets, enabling better understanding of intra-individual
306 differences in absorption, distribution and metabolism of macronutrients.
307
308 Individual human beings are not only unique in the aspect of host genome, but also in
309 the aspect of the gut microbiome, which represents the combined influence of the diet
310 and lifestyles, as well as host genetics(47, 48). Both animal and human studies have

311 demonstrated that the composition of the gut microbiome can be rapidly affected by a
312 specific dietary component exposure within four days(27, 49). Furthermore,
313 integration of machine learning algorithms with gut microbiome features have shown
314 powerful potentials to predict one's response to different dietary patterns in term of
315 postprandial glucose response(50). Zeevi *et al.* monitored the postprandial glucose
316 response in a cohort of 800 participants in Israel in response to identical meals. A
317 multidimensional data including gut microbiome features, anthropometrics, blood
318 parameters, and physical activity were integrated into a machine learning algorithm
319 that was capable of predicting personalized postprandial glucose response with the gut
320 microbiota(51). These new progresses have stimulated more research on the
321 application and integration of gut microbiome into the personalized nutrition field.
322 Results from this study may provide further evidence suggesting that n-of-1 trial is
323 feasible in characterizing individual microbiome profile.
324
325 With the aggregated data from isocaloric meal but different carbohydrate to fat ratio,
326 our study will make deeper investigations of the underlying interactions between
327 specific food components and microbiota species. Therefore, future methodological
328 studies on developing and implementing effective evaluation of personalized dietary
329 intervention could assist individuals in promoting healthy gut microbiota profile and
330 preventing cardiometabolic diseases. Another strength of the present study with
331 n-of-1 method is its flexibility which enables the study design to be personalized to

332 individuals' interests and requirements, and its high level of evidence for making

333 clinical decisions for individuals alongside systematic reviews of RCTs.

334

335 **Limitations**

336 The n-of-1 study does have limitations. Participation in feeding trial such as

337 WE-MACNUTR requires time and effort so the trial cannot be conducted in an

338 ideally controlled setting. Compliance of the participants to the intervention over time

339 is challenging, as they are all required to eat the provided foods with no extra food

340 intake throughout the feeding trial. Any extra snack or beverage intake could affect

341 individual blood glucose level. Besides, slight changes in cooking method, food

342 groups or food ingredients under inevitable circumstances would also jeopardize the

343 final results.

344

345 **Conclusions**

346 In summary, WE-MACNUTR trial, as an exemplar of nutritional n-of-1 trial, will

347 address the call for new method to advance the field of personalized nutrition.

348 WE-MACNUTR will potentially help clarify the individual postprandial glucose

349 response to diets with diverse macronutrient proportions, and help design and

350 optimize macronutrient composition in long-term dietary intervention studies. The

351 results of WE-MACNUTR will also be helpful in terms of understanding the

352 individual response of gut microbiome to macronutrients.

353 **Acknowledgements**

354 We thank all the volunteers participating in the Westlake N-of-1 Trials for
355 Macronutrient Intake (WE-MACNUTR). The authors' contributions were as follows:
356 JSZ designed the study and was the principal investigator of WE-MACNUTR; YT,
357 YM, YF and JSZ drafted the manuscript; and all authors read and approved the final
358 manuscript.

359

360

References

1. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS, Jr., Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015;102(4):780-90. Epub 2015/08/01. doi: 10.3945/ajcn.115.112581. PubMed PMID: 26224300.
2. Tay J, Thompson CH, Luscombe-Marsh ND, Wycherley TP, Noakes M, Buckley JD, Wittert GA, Yancy WS, Jr., Brinkworth GD. Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: A 2-year randomized clinical trial. *Diabetes Obes Metab*. 2018;20(4):858-71. Epub 2017/11/28. doi: 10.1111/dom.13164. PubMed PMID: 29178536.
3. Kdekian A, Alssema M, Van Der Beek EM, Greyling A, Vermeer MA, Mela DJ, Trautwein EA. Impact of isocaloric exchanges of carbohydrate for fat on postprandial glucose, insulin, triglycerides, and free fatty acid responses-a systematic review and meta-analysis. *Eur J Clin Nutr*. 2020;74(1):1-8. Epub 2019/11/27. doi: 10.1038/s41430-019-0534-6. PubMed PMID: 31767988.
4. Accurso A, Bernstein RK, Dahlqvist A, Draznin B, Feinman RD, Fine EJ, Gleed A, Jacobs DB, Larson G, Lustig RH, et al. Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. *Nutr Metab (Lond)*. 2008;5:9. Epub 2008/04/10. doi: 10.1186/1743-7075-5-9. PubMed PMID: 18397522; PubMed Central PMCID: PMCPMC2359752.
5. Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Sato M, Sugawara A, Totsuka K, Shimano H, Ohashi Y, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. *Diabetes Care*. 2009;32(5):959-65. Epub 2009/05/02. doi: 10.2337/dc08-1716. PubMed PMID: 19407076; PubMed Central PMCID: PMCPMC2671123.
6. Noakes TD, Windt J. Evidence that supports the prescription of low-carbohydrate high-fat diets: a narrative review. *Br J Sports Med*. 2017;51(2):133-9. Epub 2017/01/06. doi: 10.1136/bjsports-2016-096491. PubMed PMID: 28053201.
7. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care*. 2003;26(8):2261-7.
8. Saslow LR, Mason AE, Kim S, Goldman V, Ploutz-Snyder R, Bayandorian H, Daubenmier J, Hecht FM, Moskowicz JT. An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial. *J Med Internet Res*. 2017;19(2):e36. Epub 2017/02/15. doi: 10.2196/jmir.5806. PubMed PMID: 28193599; PubMed Central PMCID: PMCPMC5329646.

9. Bhanpuri NH, Hallberg SJ, Williams PT, McKenzie AL, Ballard KD, Campbell WW, McCarter JP, Phinney SD, Volek JS. Cardiovascular disease risk factor responses to a type 2 diabetes care model including nutritional ketosis induced by sustained carbohydrate restriction at 1 year: an open label, non-randomized, controlled study. *Cardiovasc Diabetol*. 2018;17(1):56. Epub 2018/05/02. doi: 10.1186/s12933-018-0698-8. PubMed PMID: 29712560; PubMed Central PMCID: PMC5928595.
10. Wylie-Rosett J, Aebersold K, Conlon B, Isasi CR, Ostrovsky NW. Health effects of low-carbohydrate diets: where should new research go? *Curr Diab Rep*. 2013;13(2):271-8. Epub 2012/12/26. doi: 10.1007/s11892-012-0357-5. PubMed PMID: 23266565; PubMed Central PMCID: PMC3595318.
11. Braconi D, Cicaloni V, Spiga O, Santucci A. An Introduction to Personalized Nutrition. *Trends in Personalized Nutrition*. 2019. p. 3-32.
12. Ordovas JM, Ferguson LR, Tai ES, Mathers JC. Personalised nutrition and health. *BMJ*. 2018;361:k2173. Epub 2018/06/15. doi: 10.1136/bmj.k2173. PubMed PMID: 29898881; PubMed Central PMCID: PMC6081996
interests and declare the following interests: JMO is part of Habit advisory board.
13. German JB, Zivkovic AM, Dallas DC, Smilowitz JT. Nutrigenomics and personalized diets: What will they mean for food? *Annu Rev Food Sci Technol*. 2011;2:97-123. Epub 2011/12/02. doi: 10.1146/annurev.food.102308.124147. PubMed PMID: 22129377; PubMed Central PMCID: PMC4414021.
14. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. *BMJ*. 2018;361:36-44.
15. Fito M, Melander O, Martinez JA, Toledo E, Carpeno C, Corella D. Advances in Integrating Traditional and Omic Biomarkers When Analyzing the Effects of the Mediterranean Diet Intervention in Cardiovascular Prevention. *Int J Mol Sci*. 2016;17(9). Epub 2016/09/07. doi: 10.3390/ijms17091469. PubMed PMID: 27598147; PubMed Central PMCID: PMC5037747.
16. Schork NJ, Goetz LH. Single-Subject Studies in Translational Nutrition Research. *Annu Rev Nutr*. 2017;37:395-422. Epub 2017/07/19. doi: 10.1146/annurev-nutr-071816-064717. PubMed PMID: 28715990; PubMed Central PMCID: PMC6383767.
17. McDonald S, Quinn F, Vieira R, O'Brien N, White M, Johnston DW, Snihotta FF. The state of the art and future opportunities for using longitudinal n-of-1 methods in health behaviour research: a systematic literature overview. *Health Psychol Rev*. 2017;11(4):307-23. Epub 2017/04/14. doi: 10.1080/17437199.2017.1316672. PubMed PMID: 28406349.
18. Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. *J Clin Epidemiol*. 2013;66(8 Suppl):S21-8. Epub 2013/07/17. doi: 10.1016/j.jclinepi.2013.04.006. PubMed PMID: 23849149; PubMed Central PMCID: PMC3972259.

19. Kravitz RL, Schmid CH, Marois M, Wilsey B, Ward D, Hays RD, Duan N, Wang Y, MacDonald S, Jerant A, et al. Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial. *JAMA Intern Med.* 2018;178(10):1368-77. Epub 2018/09/08. doi: 10.1001/jamainternmed.2018.3981. PubMed PMID: 30193253; PubMed Central PMCID: PMC6233756.
20. Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? *Per Med.* 2011;8(2):161-73. Epub 2011/06/23. doi: 10.2217/pme.11.7. PubMed PMID: 21695041; PubMed Central PMCID: PMC3118090.
21. Senior HE, Mitchell GK, Nikles J, Carmont SA, Schluter PJ, Currow DC, Vora R, Yelland MJ, Agar M, Good PD. Using aggregated single patient (N-of-1) trials to determine the effectiveness of psychostimulants to reduce fatigue in advanced cancer patients: a rationale and protocol. *Bmc Palliative Care.* 2013;12(1):17.
22. Moeller JD, Dattilo J, Rusch F. Applying Quality Indicators to Single-Case Research Designs Used in Special Education: A Systematic Review. *Psychology in the Schools.* 2015;52(2):139-53. doi: 10.1002/pits.21801.
23. Norcross JC, Wampold BE. What works for whom: Tailoring psychotherapy to the person. *J Clin Psychol.* 2011;67(2):127-32. Epub 2010/11/26. doi: 10.1002/jclp.20764. PubMed PMID: 21108312.
24. Stunnenberg BC, Raaphorst J, Groenewoud HM, Statland JM, Griggs RC, Woertman W, Stegeman DF, Timmermans J, Trivedi J, Matthews E, et al. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. *JAMA.* 2018;320(22):2344-53. Epub 2018/12/12. doi: 10.1001/jama.2018.18020. PubMed PMID: 30535218; PubMed Central PMCID: PMC6583079.
25. Zucker DR, Ruthazer R, Schmid CH, Feuer JM, Fischer PA, Kieval RI, Mogavero N, Rapoport RJ, Selker HP, Stotsky SA, et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. *The Journal of Rheumatology.* 2006;33(10):2069-77.
26. Parr EB, Devlin BL, Callahan MJ, Radford BE, Blankenship JM, Dunstan DW, Hawley JA. Effects of providing high-fat versus high-carbohydrate meals on daily and postprandial physical activity and glucose patterns: a randomised controlled trial. *Nutrients.* 2018;10(5):557.
27. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature.* 2014;505(7484):559-63. Epub 2013/12/18. doi: 10.1038/nature12820. PubMed PMID: 24336217; PubMed Central PMCID: PMC3957428.
28. Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, Capdevila J, Hadjigeorgiou G, Davies R, Al Khatib H, et al. Human postprandial responses to

-
- food and potential for precision nutrition. *Nat Med*. 2020;26(6):964-73. Epub 2020/06/13. doi: 10.1038/s41591-020-0934-0. PubMed PMID: 32528151.
29. Spector TD, Gardner CD. Challenges and opportunities for better nutrition science—an essay by Tim Spector and Christopher Gardner. *BMJ*. 2020;369:m2470. doi: 10.1136/bmj.m2470.
 30. The Chinese Nutrition Society. *Chinese Dietary Guidelines*. Beijing: People's Medical Publishing House; 2016.
 31. The Chinese Nutrition Society. *Chinese Dietary Reference Intakes*. Beijing: China Light Industry Press; 2013.
 32. Trumbo P, Schlicker S, Yates AA, Poos M. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids. *Journal of the American Dietetic Association*. 2002;102(11):1621-30. doi: 10.1016/s0002-8223(02)90346-9.
 33. Kravitz RL and the DEcIDE Methods Center N-of-1 Guidance Panel. *Design and Implementation of N-of-1 Trials: A User's Guide*. Rockville, MD: Agency for Healthcare Research and Quality; 2014 Feb.
 34. Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. *The Journal of Clinical Endocrinology & Metabolism*. 2015;100(3):902-10.
 35. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. *Diabetes Care*. 2010;33(6):1297-9.
 36. Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP, Lau J. Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. *J Clin Epidemiol*. 1997;50(4):401-10.
 37. Quintana M, Viele K, Lewis RJ. Bayesian Analysis: Using Prior Information to Interpret the Results of Clinical Trials. *JAMA*. 2017;318(16):1605-6. Epub 2017/10/27. doi: 10.1001/jama.2017.15574. PubMed PMID: 29067406.
 38. Jung CH, Choi KM. Impact of High-Carbohydrate Diet on Metabolic Parameters in Patients with Type 2 Diabetes. *Nutrients*. 2017;9(4). Epub 2017/03/25. doi: 10.3390/nu9040322. PubMed PMID: 28338608; PubMed Central PMCID: PMC5409661.
 39. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 2008;31 Suppl 1:S61-78. Epub 2008/01/10. doi: 10.2337/dc08-S061. PubMed PMID: 18165339.
 40. Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and

- evidence base. *Nutrition*. 2015;31(1):1-13. Epub 2014/10/08. doi: 10.1016/j.nut.2014.06.011. PubMed PMID: 25287761.
41. Santos FL, Esteves SS, da Costa Pereira A, Yancy WS, Jr., Nunes JP. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. *Obes Rev*. 2012;13(11):1048-66. Epub 2012/08/22. doi: 10.1111/j.1467-789X.2012.01021.x. PubMed PMID: 22905670.
 42. Hsu WC, Lau KH, Matsumoto M, Moghazy D, Keenan H, King GL. Improvement of insulin sensitivity by isoenergy high carbohydrate traditional Asian diet: a randomized controlled pilot feasibility study. *PLoS One*. 2014;9(9):e106851. Epub 2014/09/17. doi: 10.1371/journal.pone.0106851. PubMed PMID: 25226279; PubMed Central PMCID: PMC4167335.
 43. Kamada C, Yoshimura H, Okumura R, Takahashi K, Iimuro S, Ohashi Y, Araki A, Umegaki H, Sakurai T, Yoshimura Y, et al. Optimal energy distribution of carbohydrate intake for Japanese elderly patients with type 2 diabetes: the Japanese Elderly Intervention Trial. *Geriatr Gerontol Int*. 2012;12 Suppl 1:41-9. Epub 2012/04/28. doi: 10.1111/j.1447-0594.2011.00811.x. PubMed PMID: 22435939.
 44. Naude CE, Schoonees A, Senekal M, Young T, Garner P, Volmink J. Low carbohydrate versus isoenergetic balanced diets for reducing weight and cardiovascular risk: a systematic review and meta-analysis. *PLoS One*. 2014;9(7):e100652. Epub 2014/07/10. doi: 10.1371/journal.pone.0100652. PubMed PMID: 25007189; PubMed Central PMCID: PMC4090010.
 45. Hockaday TD, Hockaday JM, Mann JI, Turner RC. Prospective comparison of modified fat-high-carbohydrate with standard low-carbohydrate dietary advice in the treatment of diabetes: one year follow-up study. *Br J Nutr*. 1978;39(2):357-62. Epub 1978/03/01. doi: 10.1079/bjn19780045. PubMed PMID: 629924.
 46. Schulze MB, Martinez-Gonzalez MA, Fung TT, Lichtenstein AH, Forouhi NG. Food based dietary patterns and chronic disease prevention. *BMJ*. 2018;361:k2396. Epub 2018/06/15. doi: 10.1136/bmj.k2396. PubMed PMID: 29898951; PubMed Central PMCID: PMC5996879.
 47. Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, Mujagic Z, Vila AV, Falony G, Vieira-Silva S. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science*. 2016;352(6285):565-9.
 48. Celis-Morales C, Livingstone KM, Marsaux CF, Macready AL, Fallaize R, O'Donovan CB, Woolhead C, Forster H, Walsh MC, Navas-Carretero S, et al. Effect of personalized nutrition on health-related behaviour change: evidence from the Food4Me European randomized controlled trial. *Int J Epidemiol*. 2017;46(2):578-88. Epub 2016/08/16. doi: 10.1093/ije/dyw186. PubMed PMID: 27524815.

49. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. *Nature*. 2012;489(7415):242-9. Epub 2012/09/14. doi: 10.1038/nature11552. PubMed PMID: 22972297.
50. Cani PD. Human gut microbiome: hopes, threats and promises. *Gut*. 2018;67(9):1716-25. Epub 2018/06/24. doi: 10.1136/gutjnl-2018-316723. PubMed PMID: 29934437; PubMed Central PMCID: PMC6109275.
51. Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M. Personalized nutrition by prediction of glycemic responses. *Cell*. 2015;163(5):1079-94.

Table 1. Outcome and Assessment Points

Variable	Measure	Assessment point		
		T _p S1 ^a	T _p S2 ^b	T _p S3 ^c
Primary outcomes				
Continuous glucose level				
PMG		●	●	●
AUC24	FreeStyle Libre Flash Glucose Monitoring System	●	●	●
MAGE		●	●	●
Secondary outcomes				
Lipid metabolism	Blood samples			
Inflammation	Blood samples			
Oral microbiota	Saliva	√	√	√
Gut microbiota profiling	Fecal samples	√	√	√
Fecal metabolites	Fecal samples	√	√	√
Metabolomics profiling	Blood samples			
	Fecal samples	√	√	√
	Urine samples	√	√	√
Physiological characteristics				
Weight	Kubei height scale			√
Blood pressure	YUWELL YE660D upper arm sphygmomanometer			√

Abbreviations: AUC24, total area under the continues glucose monitoring curve from 0.00 to 24.00;

MAGE, mean amplitude of glycemic excursions; PMG, postprandial maximum glucose.

^aT_pS1 represents set 1.

^bT_pS2 represents set 2.

^cT_pS3 represents set 3.

● per day during intervention periods

√ before and after intervention periods

Figure 1. The Development of Personalized Nutrition. Personalized nutrition was born in the context that a conventional ‘one-size-fits-all’ approach usually fail to meet individual’s need for the nutritional requirements. “N-of-1” clinical trial is a novel study design for the research of personalized nutrition comparing with the traditional designs such as observational study and randomized controlled trial. Integration of multi-omics data including nutrigenomics, proteomics, metabolomics, microbiome and other phenotypes is key for the development of personalized nutrition.




Figure 2. Flow Diagram of the Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) Trial. The flowchart summarizes the preparation phase and the first set of the trial. Set 2 and set 3 share the same trial design as set 1 except for no blood sample collection before each wash-out or intervention period. The sequence of two types of six-day dietary interventions in each set is randomized using block randomization as LF-HC and HF-LC diets in set 1; HF-LC and LF-HC diets in set 2 and HF-LC and LF-HC diets in set 3, respectively. CGM: continuous glucose monitoring; GI diseases: gastrointestinal diseases; HF-LC: high-fat, low-carbohydrate; LF-HC: low-fat, high-carbohydrate; WE-MACNUTR: Westlake N-of-1 Trials for Macronutrient Intake.




Figure 3. The Timeline of the Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR) Trial. The timeline illustrates a preparation period for participants recruitment, a baseline data collection period, and three feeding trial periods. The first set of the trial consists of two wash-out periods (highlighted in green) and two randomized dietary intervention periods (highlighted in grey). In all three sets of the trial, both wash-out and intervention periods last for 6 days respectively.




Figure 4. Representation of the Hierarchical Bayesian Estimation for the Primary Outcomes at Both Individual and Population Level (combination of single patient studies). The observed repeated measurements of the postprandial peak glucose on a given patient are combined into a sample mean and sample variance. The model assumes that the patients' measurements follow a normal distribution centered about that patient's true mean effect (μ_i) with variance σ_1^2 . At the population level, the various patients' true mean (μ_i) are assumed to follow a normal distribution centered about an overall population mean (μ_0) with between-patient variance τ^2 . For the Bayesian specification, prior distributions are assigned for β , μ_0 , σ_1^2 , and τ^2 . In the present study, these prior distributions are standard non-informative prior distributions. X means the independent variable: dietary pattern (high-fat and low-carbohydrate vs. low-fat and high-carbohydrate). Secondary and exploratory outcomes will be analyzed similarly. PMG: postprandial maximum glucose.

